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Abstract
Objective—To determine if a contingency management intervention using the ethyl glucuronide 
(EtG) alcohol biomarker resulted in increased alcohol abstinence in outpatients with co-occurring 
serious mental illnesses. Secondary objectives were to determine if contingency management was 
associated with changes in heavy drinking, treatment attendance, drug use, cigarette smoking, 
psychiatric symptoms, and HIV-risk behavior.
Method—Seventy-nine (37% female, 44% non-white) outpatients with serious mental illness and 
alcohol dependence receiving treatment as usual completed a 4-week observation period and were 
randomized to 12-weeks of contingency management for EtG-negative urine samples and 
addiction treatment attendance, or reinforcement only for study participation. Contingency 
management included the variable magnitude of reinforcement “prize draw” procedure contingent 
on EtG-negative samples (<150 ng/mL) three times a week and weekly gift cards for outpatient 
treatment attendance. Urine EtG, drug test, and self-report outcomes were assessed during the 12-
week intervention and 3-month follow-up periods.
Results—Contingency management participants were 3.1 times (95% CI: 2.2, 4.5) more likely to 
submit an EtG-negative urine test during the 12-week intervention period, attaining nearly 1.5 
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weeks of additional abstinence relative to controls. Contingency management participants had 
significantly lower mean EtG levels, reported less drinking and fewer heavy drinking episodes, 
and were more likely to submit stimulant-negative urine and smoking-negative breath samples, 
relative to controls. Differences in self-reported alcohol use were maintained at the 3-month 
follow-up.
Conclusions—This is the first randomized trial utilizing an accurate and validated biomarker 
(EtG) to demonstrate the efficacy of contingency management for alcohol dependence in 
outpatients with serious mental illness.
Alcohol misuse is the third leading preventable cause of death in the U.S. and accounts for 
an estimated $223.5 billion annually (1, 2), yet 85% of those with an alcohol use disorders 
never receive treatment (3). Some populations, such as those with serious mental illnesses, 
including schizophrenia spectrum, bipolar, and major depressive disorders, are at high risk 
of suffering from alcohol use disorders, with lifetime prevalence as high as 44% (4). Among 
those with serious mental illness, alcohol use negatively impacts psychiatric symptoms and 
contributes to high rates of homelessness, psychiatric hospitalization, HIV infection, 
cigarette smoking, and drug abuse (5, 6). Psychosocial treatments demonstrate reductions in 
alcohol and drug use in adults with serious mental illness (7, 8); however, few are widely 
available due to their relatively high costs, need for extensive training and fidelity 
monitoring, and organizational barriers (9, 10).
Contingency management is an intervention in which reinforcers such as vouchers or prizes 
are provided, typically multiple times per week, when individuals demonstrate drug 
abstinence (11). Point-of-care urine drug tests allow for implementation of contingency 
management because they are inexpensive, provide immediate results, and verify abstinence 
for two days or more. While contingency management is well-established as an intervention 
for reducing drug use (11, 12), few studies have investigated contingency management as a 
treatment for alcohol use disorders (13–15). This is primarily due to the lack of an alcohol 
biomarker that can verify abstinence for two days or more. Previous studies have used 
alcohol breath tests, including mobile video recorded breathalyzers, which can only detect 
use for approximately 12 hours after ingestion (13, 15), or transdermal alcohol sensors, 
which provide continuous monitoring of alcohol use (14). While these studies have observed 
reductions in drinking, to date, no randomized trial has investigated the efficacy of 
contingency management for alcohol use disorders using a biomarker that can verify 
abstinence for two days or more and can be feasibly conducted in a treatment setting.
Ethyl glucuronide (EtG) is an alcohol metabolite produced by the liver that at low cutoffs 
(100–200 ng/mL) can be detected in urine for up to five days after drinking (16, 17). EtG 
tests can be conducted in reference laboratories, in clinical settings using a benchtop 
analyzer, or, more recently, using a point-of-care dipcard. We have demonstrated that an EtG 
immunoassay can be conducted accurately at low cutoffs (100–200 ng/mL) using a benchtop 
analyzer in an outpatient clinic (18) and that EtG can be used to implement a contingency 
management intervention targeting alcohol (19).
Previous research indicates that contingency management is a feasible and effective 
intervention for adults with substance use disorders and serious mental illness (20–22). In 
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the only large trial (N=176) of contingency management for outpatients with drug 
dependence and serious mental illness, those who received contingency management for 
stimulant abstinence were 2.4 times more likely to submit a stimulant negative urine sample 
during the intervention, relative to those in the control condition (22). Contingency 
management participants also reported higher levels of stimulant abstinence during a three 
month follow-up and had lower levels of alcohol use, cigarette smoking, psychiatric 
symptoms, and inpatient psychiatric hospitalizations, relative to controls (22, 23). A cost-
benefit analysis indicated that these clinical benefits offset the costs of the intervention (24). 
Despite these positive findings, a weakness of this study was a contingency management 
attrition rate of 41%.
The objective of this study was to determine if a contingency management intervention that 
provided reinforcers for alcohol abstinence assessed by EtG, and reinforcers for addiction 
treatment attendance resulted in increased alcohol abstinence in adults with alcohol use 
disorders and serious mental illness receiving treatment as usual in a community mental 
health center. Secondary outcomes were other measures of alcohol use, addiction treatment 
attendance, drug use, psychiatric symptoms, cigarette smoking, and HIV-risk behavior. A 
pre-randomization induction period was used, along with other strategies, to reduce attrition 
in the randomized sample. To our knowledge, this is the first adequately powered 
randomized trial of contingency management for alcohol use disorders using an appropriate 
alcohol biomarker and the second of contingency management in serious mental illness 
among adults.
METHOD
Participants
Participants were recruited from a multisite community mental health and addiction 
treatment agency in Seattle, WA, and met DSM-IV-TR criteria for alcohol dependence, and 
schizophrenia, schizoaffective disorder, bipolar I or II, or recurrent major depressive disorder 
assessed by the Mini-International Neuropsychiatric Interview. Other eligibility criteria were 
alcohol use on >4 of the last 30 days and enrollment in outpatient addiction group treatment 
at the agency. Exclusions were comorbid drug dependence, except nicotine, or medical or 
psychiatric severity that would compromise safe participation.
As described in the consort diagram (see supplemental figure), 237 individuals were 
screened for eligibility. Of the 121 eligible participants, 84 successfully completed the 4-
week induction period (described below). Five of these individuals were allocated to the 
contingency management intervention to set the initial magnitude of reinforcement for the 
non-contingent condition and were not included in analyses. Seventy-nine participants were 
randomized to intervention groups and comprise the intent-to-treat sample. Participants 
provided written informed consent and procedures were approved by the University of 
Washington’s Human Subjects Division.
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Design and Procedure
This study employed a 4-week induction observation period (weeks 1–4), designed to 
increase retention after randomization, followed by a 12-week randomized controlled trial of 
contingency management (weeks 5–16), including a qualitative interview at week 16, with a 
3-month follow-up (weeks 17–28). Participants received treatment-as-usual throughout the 
study and were randomized to contingency management, where they received reinforcers for 
EtG-negative urine samples and addiction treatment attendance (n=40) or the non-contingent 
control group (non-contingent; n=39), in which they received reinforcers regardless of EtG 
results and treatment attendance. The Urn-randomization procedure was used to allocate 
participants to intervention groups balanced on mood vs. psychotic disorder, level of alcohol 
use 30 days before baseline, and drug use 30 days before baseline. Randomized participants 
completed monthly follow-up interviews for three months.
Measures
At the baseline interview, participants completed the Mini-International Neuropsychiatric 
Interview to assess for alcohol use, drug use, mood and psychotic disorders, and an 
assessment of demographics. At baseline and weeks 4, 8, 12, 16, 20, 24, and 28, participants 
completed the Addiction Severity Index-Lite to assess days of alcohol use, drinking to 
intoxication and drug use, the Clinical Monitoring Form, Brief Symptom Inventory, and 
Positive and Negative Syndrome Scale for Schizophrenia to assess psychiatric symptom 
severity, the HIV Risk-Taking Behavior Scale, and the Fagerström Test for Nicotine 
Dependence. Participants received $20–$30 for these interviews.
Participants provided urine and breath samples three times per week during the induction 
and intervention, and once every four weeks during follow-up. The primary alcohol use 
outcome was urine EtG level as measured by the Diagnostic Reagents Incorporated EtG 
enzyme immunoassay conducted onsite using a Thermo Fisher Indiko analyzer (Fremont, 
CA). Samples were considered alcohol negative if EtG < 150 ng/mL (16, 17). Tests were 
conducted using EtG 100 ng/mL, 500 ng/mL, 1000 ng/mL, 2000 ng/mL, and Negative 
calibrators and EtG 100 ng/mL and 375 ng/mL controls. Calibrations occurred weekly. 
Samples were analyzed on the day of collection. Participants were instructed to avoid non-
beverage sources of ethanol, such as mouthwash and cough syrup. Participants were 
escorted to the bathroom and samples were checked for appropriate temperature after 
collection.
Urine samples were tested for amphetamine, methamphetamine, cocaine, marijuana, and 
opiate use (Integrated E-Z Split Key Cup II, Innovacon, Inc, San Diego, CA). Breath 
samples were also tested for carbon monoxide (CO) analysis (Bedfont-Smokerlyzer Micro-
IV) (smoking positive CO ≥3ppm) (25).
At every study visit the Alcohol Timeline Followback method (26) was used to assess hours 
since the last drinking episode and the number of standard drinks consumed at the last 
drinking episode in the prior five days. These data were used to assess the presence of heavy 
drinking (women > 3 standard drinks, men > 4 standard drinks) during the prior five days. 
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Participants completed a brief qualitative interview assessing the feasibility and effectiveness 
of the study at week 16.
Study Interventions
Treatment as Usual—Participants were required to be enrolled in state-certified 
outpatient addiction treatment where they received the same curriculum during group 
counseling sessions two to four times weekly for twelve weeks or more. This included 
psychoeducation about the causes of addiction, relapse prevention, and other relevant topics, 
such as wellness. Participants could receive mental health care which involved meeting with 
a case manager once per week and psychiatric medication management, group treatment, 
and housing and vocational services as appropriate. Self-reported pre-randomization 
utilization of addiction treatment as usual care did not vary by group.
Induction period—After the baseline interview, participants entered a 4-week induction 
where they received reinforcers contingent on providing urine samples three times per week 
regardless of EtG results. Participants received three “prize draws” (described below) for 
each urine sample provided. The induction period has been used in previous studies to 
decrease attrition in the randomized sample by selecting for randomization only those who 
can attend brief study appointments and are currently using alcohol (27, 28). Participants 
who attended at least one visit during the fourth week and provided at least one EtG-positive 
urine sample at any time during induction were randomized. Individuals who did not 
initially meet criteria for randomization were allowed to re-enroll in the study. Re-enrolled 
individuals completed a second baseline and induction period. Ten participants were re-
enrolled and six were randomized.
Contingency Management—Participants in contingency management received the 
variable magnitude of reinforcement procedure each time they tested negative for EtG. This 
well-researched procedure involves making “prize draws” from a container of tokens 
representing different magnitudes of reinforcement (11). Fifty percent read “good job” (no 
prize). The other 50% were associated with a tangible prize (41.8% read “small” $1.00 
value, 8.0% read “large” $20.00 value, and 0.2% read “jumbo” $80.00 value).
Participants provided urine samples three times per week for 12 weeks. They earned at least 
three prize draws for each EtG-negative urine sample submitted (EtG < 150 ng/mL). One 
additional prize draw was earned for each week of continuous alcohol abstinence (three 
consecutive EtG-negative samples). Participants who missed an appointment or had an EtG-
positive sample did not earn prize draws and had a “reset” to three prize draws when their 
next negative sample was submitted. Following a reset, participants could return to the 
number of prize draws at which the reset occurred by providing three consecutive EtG-
negative samples. Participants received gift cards for attending all ($10) or at least one ($5) 
of their addiction groups each week.
Non-Contingent Reinforcement—Non-contingent participants submitted urine samples 
three times a week for 12 weeks, but received prize draws for each urine sample submitted, 
regardless of EtG results. Consistent with previous studies (22, 29), the number of prize 
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draws they received was equal to the average number of prize draws earned by the 
contingency management group in the previous week. This procedure assured that groups 
received an equal number of prize draws. Non-contingent participants did not need to attend 
addiction treatment to earn gift cards; instead they received gift cards equal to those earned 
by the contingency management group during the previous week.
Reinforcers and Earnings—The total average values of prizes earned by the non-
contingent (Mean=$147.54, SD=$143.19) and contingency management (Mean=$175.03, 
SD=$183.17) groups were not significantly different.
Attrition—Individuals who missed nine consecutive study visits (3 weeks) during the 
intervention phase were considered dropouts. These individuals could complete follow-up 
interviews and were included in the intent-to-treat analyses.
Data Analysis
We used chi-square tests for categorical variables and t tests for continuous variables to 
examine baseline differences across groups. Analyses were conducted on the intent-to-treat 
sample. Generalized estimation equations were used to analyze outcomes that were collected 
over time. The maximum likelihood estimation procedure was used (30). To protect against 
Type-I error, analyses utilized bi-directional tests despite our uni-directional hypotheses. 
Odds ratios with 95% confidence intervals are presented for binary outcomes, and 
unstandardized regression coefficients with 95% confidence intervals are presented for 
continuous outcomes. These methods of analysis have been used in many contingency 
management trials and are effective and efficient methods of analyzing outcomes across time 
nested within participants (22, 29). Analyses controlled for baseline levels of the outcome 
being analyzed.
Multiple imputation procedures were used to handle missing data. This approach has 
advantages over single imputation, listwise deletion, or other techniques (31, 32) in 
conjunction with generalized estimation equation analyses. We present listwise deletion 
analyses first and include the multiple imputation analyses in Table 3 to provide confidence 
bounds for the location of the true treatment effect. Preliminary analyses identified several 
variables that predicted missingness due to intervention dropout. We used these variables 
during the imputation phase to ensure our ‘missing at random’ assumption was tenable. 
While there is no test for whether missing data are truly ‘missing at random’ versus ‘missing 
not at random,’ our inclusive strategy for auxiliary variables during imputation made for a 
tenable assumption that data were ‘missing at random.’ Multiple imputation procedures used 
a regression-based approach to fill in the missing values to produce multiple datasets. Fifty 
datasets were analyzed for each analysis to maximize statistical efficiency. Parameters and 
standard errors were combined using Rubin’s rules (33). Analyses were performed using 
Stata 14.1 (StataCorp, College Station, TX).
RESULTS
Twenty-six (65%) contingency management and 29 (74%) non-contingent participants 
completed the intervention phase, a non-significant difference. Thirty (75%) of the 
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contingency management participants and 30 (77%) of the non-contingent participants 
attended at least one of three follow-up assessments and 42 (53%) participants attended all 
follow-up assessments. Demographic and clinical characteristics of the sample did not differ 
by group (see Table 1).
EtG and Self-Reported Alcohol Use
As Figure 2 illustrates, individuals randomized to contingency management had a mean 
longest duration of alcohol abstinence (number of consecutive EtG-negative urine samples) 
more than twice as long as controls (contingency management: Mean=8.56, SD=12.59; non-
contingent: Mean=4.11, SD=1.22; F(3)=5.55, df=1, 76, p<0.05), with approximately 1.5 
weeks of additional abstinence. Contingency management participants were 3.13 times 
(95% CI: 2.18, 4.50, p<0.05) more likely to submit an EtG-negative urine sample during the 
intervention period relative to controls (see Figure 1). Contingency management participants 
had significantly lower EtG levels during the intervention period relative to controls 
(B=325.93; 95% CI: 213.35, 438.51, p<0.05). While group differences on both the binary 
and continuous versions of EtG persisted into follow-up (see Table 2), these differences were 
non-significant. Multiple imputation analyses verified results of EtG analyses during 
intervention and follow-up (Table 3).
Contingency management participants had significantly fewer days of any drinking (B=8.29; 
95% CI: 3.97, 12.60, p<0.05) and drinking to intoxication (B=6.43; 95% CI: 2.40, 10.47, 
p<0.05) throughout the intervention period, relative to controls (see Table 2). They were 
3.48 times (Odds ratio=3.48; 95% CI: 2.32, 5.23, p<0.05) less likely to report recent heavy 
drinking during the intervention period, relative to controls. These findings persisted into the 
follow-up period (days of drinking, B=7.40; 95% CI: 3.52, 11.29, p<0.05, days of 
intoxication, B=5.69; 95% CI: 2.57, 8.80, p<0.05, heavy drinking in last 5 days, Odds 
Ratio=4.90; 95% CI: 1.78, 13.47, p<0.05). These differences were significant using the 
multiple imputations during treatment and follow-up (Table 3).
Secondary Outcomes
Contingency management participants were more likely to submit stimulant-negative urine 
tests during the intervention (Odds ratio=3.19, 95% CI: 1.99, 5.10, p<0.05) and follow-up 
periods (Odds ratio=4.59, 95% CI: 1.24, 17.08, p<0.05), and self-reported fewer days of 
stimulant drug use during the intervention period (B=2.22, 95% CI: 0.34, 4.10, p<0.05). 
Multiple imputation analyses found similar results for stimulant drug tests (Table 3). The 
multiple imputation analyses replicated the effect size of self-reported days of stimulant drug 
use, but the treatment effect for the intervention period was not significant (Table 3).
Among the 54 smokers identified by smoking-positive self-report or carbon monoxide 
samples at baseline, contingency management participants were 5.4 times more likely to 
submit a smoking-negative breath sample, relative to controls during the intervention period 
(Odds ratio=5.39, 95% CI: 1.93, 15.0, p<0.05). The multiple imputation model represented 
an attenuation of these findings (Table 3). This difference was not significant during the 
follow-up period. Group differences on other secondary outcomes including addiction 
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treatment attendance, opioid and marijuana use, psychiatric symptoms, HIV risk behavior, 
and self-reported cigarette smoking were not statistically significant.
Patient Perspective
The participant was a 52 year-old African-American man diagnosed with major depressive 
disorder. He wanted to stop using alcohol but struggled to stop drinking due to his 
unpredictable housing situation. He was abstinent for 11 weeks during the contingency 
management intervention and earned over $700 in gift cards and prizes. He expressed 
appreciation for the small pragmatic prizes, such as laundry detergent, toothpaste and 
deodorant, because they lessened his day-to-day worries and expenses. By the end of the 
intervention, he obtained sober housing and was regularly attending outpatient treatment.
DISCUSSION
This is the first adequately powered randomized trial of contingency management for 
alcohol use disorders utilizing an accurate alcohol biomarker. Those who received 
contingency management were three times more likely to submit an EtG-negative urine 
sample during the intervention period, and they attained approximately 1.5 weeks of 
additional abstinence, relative to controls. Those who were assigned to contingency 
management had an average EtG level that was approximately 300 ng/mL lower than 
controls during the intervention period. These differences are large and clinically significant. 
Self-report data corroborated EtG results, with contingency management participants 
reporting fewer days of alcohol use, drinking to intoxication, and episodes of heavy drinking 
during the intervention and follow-up periods. Results are consistent with reductions in 
drinking during contingency management (13–15), as well as during follow-up (14) reported 
by others. This study provides further evidence of post-intervention benefits of contingency 
management for alcohol use (14).
This is the second trial to investigate the efficacy of a contingency management intervention 
focused on promoting abstinence from alcohol or drug use in adults with serious mental 
illness (22). Both trials demonstrated that contingency management is a powerful procedure 
for reducing substance use when added to treatment as usual at a community mental health 
center. This study also replicates our previous findings of group differences in non-targeted 
drug use and cigarette smoking (22, 23). We did not observe group differences in other 
outcomes, such as psychiatric functioning or HIV-risk behavior. However, this could be due 
to a lack of statistical power, given the relatively small sample size.
The contingency management completion rate (65%) was superior to our previous study in 
adults with serious mental illness and stimulant dependence (41%) (22) and is comparable, 
if not superior, to contingency management studies in populations without serious mental 
illness (29). We implemented a number of strategies to reduce attrition including requiring 
participants be in treatment as usual, increasing the minimum number of prize draws for 
each abstinent urine sample from one to three, and utilizing a four-week induction period 
prior to randomization. While differences in completion rates could be due to differences in 
study populations, and the first two strategies may have reduced attrition, we hypothesize 
that the induction period played an important part in the improved contingency management 
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completion observed in this study. Aside from the methodological advantages, the induction 
period may have clinical relevance. It allows clinicians to identify individuals who are most 
likely to benefit from contingency management (i.e., current alcohol users who can attend 
frequent brief intervention visits) and allows individuals to receive reinforcers before 
abstinence is required. Those who cannot complete the induction are unlikely to benefit from 
contingency management, but might benefit from other interventions.
Limitations of this study include the relatively small sample size, which may have limited 
our ability to observe statistically significantly differences during follow-up, as well as 
differences in psychiatric symptoms. Also, while we observed reductions in smoking, we did 
not observe group differences in smoking quit rates. Recruitment from one agency and the 
use of the induction period to restrict randomization to individuals best suited to contingency 
management might limit the generalizability of study results. In terms of age (Mean=45.38, 
SD=10.20) and gender (37% female), the sample is consistent with other studies of those 
with co-occurring disorders (21). Another limitation was the use of a $30,000 onsite urine 
analyzer to conduct EtG tests, and an additional approximate cost of $2.50 per test due to 
chemicals required for testing. The recent development of inexpensive ($4) point-of-care 
EtG immunoassay dipcard tests (Confirm Biosciences, San Diego, CA) further improves the 
feasibility of an EtG-based contingency management intervention. Funding for reinforcers 
and urine tests can be a barrier to implementation. However, this barrier is likely 
surmountable as cost-effectiveness studies of contingency management in those with and 
without serious mental illness support the intervention’s cost-savings (24, 34, 35).
Results of this study strongly support the efficacy of an EtG-based contingency management 
intervention for alcohol use disorders. Group differences in alcohol use observed in this 
study, and positive outcomes of our previous trial of contingency management targeting 
stimulant use, suggest that contingency management may be a particularly effective 
intervention for those with co-occurring serious mental illness and substance use disorders, a 
high-cost and difficult to engage population.
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FIGURE 1. 
Group Differences in Aclohol-Negative Ethyl Glucuronide Urine Samples across the 12-
week Intervention Period.
Note: Participants assigned to the contingency management group were 3.13 (95% CI: 2.18, 
4.50, p<0.05) times more likely to submit an alcohol-negative urine sample relative to 
controls during the 12-week treatment period. While the use of multiple imputation 
techniques allowed us to include the entire sample (N=79) in our inferential statistical tests 
for treatment outcomes, in this figure we display the original raw data without imputation.
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FIGURE 2. 
Group differences in longest duration of continuous alcohol abstinence.
Note: The Figure represents the mean number of continuous alcohol-negative ethyl 
glucuronide alcohol tests attained by the contingency management and non-contingent 
control groups during the intervention period, F (3)=5.55, df=1, 76, p<0.05.
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TABLE 3
Multiple imputation results for primary and secondary outcomes during the intervention and post-intervention 
follow-up time periods (N=79).
Intervention Follow-up
Outcome Variable Estimate CI (95%) Estimate CI (95%)
% Alcohol Negative urine sample* Odds ratio=2.86 2.12:3.87 Odds ratio=2.60 0.97:6.93
EtG Value (ng/mL)** B=325.70 223.86:427.53 B=283.27 −58.84:625.18
Self-reported days Alcohol Use Last 30 days B=7.22 3.30:11.14 B=7.21 3.30:11.14
Self-reported days Alcohol Intoxication Last 30 Days B=4.58 0.18:8.99 B=5.27 2.30:8.24
Self-reported % Heavy drinking last 5 days Odds ratio=2.96 2.09:4.18 Odds ratio=4.11 1.54:10.93
% Stimulant Negative Urine Tests Odds ratio=2.79 2:03:3.84 Odds ratio=2.99 0.98:8.49
Self-reported Days Stimulant Use in Last 30 Days B=1.86 0.66:5.09 B=2.89 0.98:8.49
% Smoking Negative Carbon Monoxide Samples (N=54) Odds ratio=2.62 1.16:5.91 Odds ratio=5.58 0.46:67.92
Note: Bold text indicates statistically significant group differences, p<0.05.
*Alcohol negative urine sample equals ethyl glucuronide < 150 ng/mL.
**
EtG: ethyl glucuronide immunoassay value ranging from 0 to 2,000 ng/mL
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